Nath Bio-GenesQ4 FY26
Nath Bio-Genes Q4 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹155P/E: 8.6Market Cap: ₹291 CrSector: Agricultural Food & other Products
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
No
0 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26.
- →Paddy volume growth is anticipated at 20-25%, reflecting strong performance.
- →Maize is a key growth driver, with significant volume surge of 54% in FY26 and expected to maintain strong growth.
- →Overall top-line (revenue) growth for FY27 is conservatively projected between 15-20%.
- →EBITDA margins and net profit margins are expected to maintain a slight upward trend.
- →The company is confident in scaling operations sustainably, backed by a stable production base, growing market presence, and robust product pipeline.
- →International business is nascent but growing; from INR 15 crores currently in Uzbekistan, long-term international revenue is targeted at 10-15% of total sales.
- →Inventory build-up is planned to meet anticipated demand, reinforcing growth outlook.
Margin guidance
Category 3- →Revenue growth for FY27 is expected between 15-20%, driven by strong volume growth in cotton (22%), paddy (25%), and maize (54%).
- →EBITDA margin is anticipated to maintain or show a slight upward trend, leading to improved net profit margins.
- →PAT performance is expected to remain healthy, with slight increase in marketing and finance costs considered manageable.
- →EPS has doubled over five years (INR 11.3 in FY22 to INR 23.42 in FY26), reflecting sustained value creation; growth momentum to continue.
- →Company maintains a conservative outlook, preferring to under-commit and over-perform.
- →Growth aided by expanded product portfolio, market penetration, especially in maize, and international expansion (Uzbekistan contributing INR 15 crores).
- →Sales and marketing spend will be commensurate with revenue growth, maintaining healthy margins.
- →Overall, Nath Bio-Genes is confident of sustained quality growth and improved profitability in FY27 and beyond.
3 more insights locked — sign up free to unlock
Fundraise plans
- →No specific mention of any current or planned fundraising through debt or equity in the call.
- →Finance costs increased due to deliberate working capital investment for inventory build-up, but this is managed from existing resources.
- →The company has substantial cash and bank balances (INR 707 million) and bank deposits (INR 70-80 crores), indicating no urgent need for external fundraising.
- →CapEx investments are minimal and focused only on land bank and vehicles, avoiding large capital expenditures.
- →The company prefers conservative commitments and aims for organic growth rather than leveraging through debt or equity issuance at this time.
Order book
The transcript from the Q4 FY26 earnings call of Nath Bio-Genes Limited does not explicitly mention the current or expected order book or pending orders in specific numeric terms. However, some relevant points indicating the company's outlook on production, inventory, and sales order status are:
- Inventory has increased as the company is building stock ahead of the upcoming season, expecting sales to liquidate the inventory over the next two years.
- Production is being stabilized with improved yield, contributing to increased sales (cotton Bt volume grew 22% YoY).
- The company anticipates top-line growth of 15-20% for FY27, reflecting confidence in demand.
- International market expansion is in early stages; Uzbekistan contributed INR 15 crores for the first time, signaling potential new markets.
- Working capital investment has increased to support inventory build-up for FY27, indicating preparation for fulfilling expected orders.
No specific values for order book or pending orders were disclosed.
Capex plans
No- →Nath Bio-Genes follows a conservative CapEx policy focusing mainly on land bank and vehicles necessary for sales and production.
- →The company avoids heavy investments in processing plants and storage facilities, opting instead for rentals, as the need for such infrastructure is limited and seasonal (e.g., maize requires about 15-20 days of processing).
- →For FY27, there are no significant planned CapEx investments in processing capacity, cold storage, or new geographies.
- →The strategy favors minimal CapEx with an emphasis on operational efficiency and leveraging existing external infrastructures rather than owning them.
How does Nath Bio-Genes rank vs peers in Agricultural Food & other Products?
Pro feature1Nath Bio-Genes
Rev 3Mar 3
See full Agricultural Food & other Products sector rankings
How does Nath Bio-Genes rank in Agricultural Food & other Products?
Compare Nath Bio-Genes against every Agricultural Food & other Products company (Q4 FY26) on revenue, margins and earnings-call signals.